Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Vacca

Showing results (311-320 of 347) with videos related to

Pageof 35
Sort By:
Frontiers in Immunology|April 17, 2020
Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical PhenotypeRiccardo Scarpa, Federica Pulvirenti, Antonio Pecoraro, et al.
Frontiers in Immunology|July 31, 2025
Development and implementation of Phleos, a web-based tool for the data collection on Hypereosinophilic syndrome: the Italian Network on HES (INHES) study protocolStefania Nicola, Marco Caminati, Richard Borrelli, et al.
European Journal of Internal Medicine|June 28, 2025
Incidence and prevalence of systemic lupus erythematosus across Italian referral centers and its clinical burden in terms of disease severity, treatment and hospitalization: The ESCULAPIO studyIrene Mattioli, Michela Gasparotto, Alberto Bergamini, et al.
Haematologica|November 8, 2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersFrancesco Zaja, Stefano De Luca, Umberto Vitolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic targetRoberto Ria, Ivana Catacchio, Simona Berardi, et al.
Neoplasia (New York, N.Y.)|December 12, 2018
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?Ilaria Saltarella, Maria Antonia Frassanito, Aurelia Lamanuzzi, et al.
The Journal of Pathology|August 1, 2012
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patientsAntonio Basile, Michele Moschetta, Paolo Ditonno, et al.
Frontiers in Medicine|February 8, 2021
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency DepartmentAntonio Giovanni Solimando, Nicola Susca, Paola Borrelli, et al.
European Journal of Haematology|November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian expertsFrancesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Pageof 35

Showing results (311-320 of 347) with videos related to

Sort By:
Pageof 35
Frontiers in Immunology|April 17, 2020
Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical PhenotypeRiccardo Scarpa, Federica Pulvirenti, Antonio Pecoraro, et al.
Frontiers in Immunology|July 31, 2025
Development and implementation of Phleos, a web-based tool for the data collection on Hypereosinophilic syndrome: the Italian Network on HES (INHES) study protocolStefania Nicola, Marco Caminati, Richard Borrelli, et al.
European Journal of Internal Medicine|June 28, 2025
Incidence and prevalence of systemic lupus erythematosus across Italian referral centers and its clinical burden in terms of disease severity, treatment and hospitalization: The ESCULAPIO studyIrene Mattioli, Michela Gasparotto, Alberto Bergamini, et al.
Haematologica|November 8, 2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersFrancesco Zaja, Stefano De Luca, Umberto Vitolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic targetRoberto Ria, Ivana Catacchio, Simona Berardi, et al.
Neoplasia (New York, N.Y.)|December 12, 2018
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?Ilaria Saltarella, Maria Antonia Frassanito, Aurelia Lamanuzzi, et al.
The Journal of Pathology|August 1, 2012
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patientsAntonio Basile, Michele Moschetta, Paolo Ditonno, et al.
Frontiers in Medicine|February 8, 2021
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency DepartmentAntonio Giovanni Solimando, Nicola Susca, Paola Borrelli, et al.
European Journal of Haematology|November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian expertsFrancesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Pageof 35